by TractManager | Jan 25, 2021 | News
SANTA MONICA, CA and HOUSTON, TX – January 25, 2021 —(PRNEWSWIRE)— symplr, a leading global healthcare governance, risk management, and compliance (“GRC”) software-as-a-service (“SaaS”) platform, backed by Clearlake Capital Group, L.P. (together with its affiliates,...
by TractManager | Jan 25, 2021 | Health Technology Assessment
Focus of the Report: Vagus nerve stimulation (VNS) is used as an adjunct to antiepileptic drugs (AEDs) for the treatment of seizures uncontrolled by medical management, epileptic surgery, or other interventions such as ketogenic diets.Technology Description: VNS...
by TractManager | Jan 25, 2021 | Emerging Technology Report
Lupkynis (voclosporin) is an oral calcineurin-inhibitor immunosuppressant indicated in combination with a background immunosuppressive therapy regimen for the treatment of adult patients with active lupus nephritis (LN).If you have a Hayes login, click here to view...
by TractManager | Jan 22, 2021 | News
The Food and Drug Administration (FDA) has approved Cabenuva (cabotegravir and rilpivirine, injectable formulation; ViiV Healthcare) as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace a current...
by TractManager | Jan 21, 2021 | Clinical Utility Evaluation
This report evaluates the clinical utility of whole genome sequencing (WGS) and whole exome sequencing (WES) in patients with a primary phenotype of intellectual disability (ID). In general, ID may be associated with other neurological disorders, various genetic...
Recent Comments